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Abstract
The Calcium-Sensing Receptor is a key component of Calcium/Parathyroid hormone homeostatic
system that helps maintain appropriate plasma Ca2+ concentrations. It also has a number of non-
homeostatic functions, including cell cycle regulation through the p38 MAPK pathway, and recent
studies have indicated that it is required for Ca2+ mediated growth arrest in pancreatic carcinoma
cells. Some pancreatic cancers produce pathogenic amounts of parathyroid like hormones,
however, which significantly increase Ca2+ plasma concentrations and might be expected to block
further cell growth. In this study we have investigated the expression and function of the p38 MAPK
signaling pathway in Ca2+ sensitive (T3M-4) and insensitive (FA6) pancreatic cancer cell lines. FA-6
cells, which are derived from a pancreatic adenocarcinoma that secretes a parathyroid hormone
related peptide, exhibit only very low levels of p38 MAPK expression, relative to T3M-4 cells.
Transfecting FA-6 cells with a p38 MAPK expression construct greatly increases their sensitivity to
Ca2+. Furthermore, the reduction of p38 MAPK in T3M-4 cells significantly reduces the extent to
which high levels of Ca2+ inhibit proliferation. These results suggest that the low levels of p38 MAPK
expression in FA-6 cells may serve to reduce their sensitivity to high concentrations of external
Ca2+ that would otherwise block proliferation.
Background
The Calcium -Sensing Receptor (CaR) was cloned a dec-
ade ago, and has proven to be an important component
in Ca2+ homeostasis through its regulation of parathyroid
hormone (PTH [1]). It also has a number of non-homeo-
static functions including the control of ion channels and
hormone secretion, and also in the regulation of cell cycle
events [2]. Most notably, Ca2+ stimulation of CaR pro-
motes the proliferation of osteoblasts [3] and fibroblasts
[4], together with a number of malignant cell types
including myeloma and ovarian surface cancer [5], prob-
ably through activation of the EGF receptor [6]. Con-
versely, the growth of some cells is blocked, including
colonic [7] and some pancreatic carcinomas [8]. In each
case signaling through CaR is mediated by a specific
Mitogen activated protein kinase (MAPK) pathway, char-
acterized by and dependant upon p38 MAPK.
Hypercalcaemia due to the degradation of bone matrix by
osteoclasts is commonly associated with a number of
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malignancies, most notably those of the breast [9], lung
[10], testis and kidney [11], although it is also a feature of
some pancreatic cancers [12]. The mechanism frequently
underlying this process is the secretion of PTH-related
peptide (PTHrP) by cancer cells [13]. This activates oste-
oblast cells that in turn promote osteoclasts to degrade the
bone matrix, releasing large amounts of Ca2+. High
Ca2+concentrations then stimulate further PTHrP secre-
tion, resulting in increasingly severe bone loss and hyper-
calcaemia, and in many cases promotes further tumour
growth [13,14].
In view of the generalized anti-proliferative effect of Ca2+
on pancreatic adenocarcinoma cells (PACs), it is surpris-
ing that some PACs actually secrete high levels of PTHrP,
thereby promoting hypercalcaemia. Here we compare two
PAC derived cell lines, FA-6 [12] and T3M-4 [15], which
have similar characteristic except that FA-6 secretes high
levels of PTHrP [12]. Our results indicate that the relative
insensitivity of FA-6 cells to Ca2+ is mediated by a consti-
tutively low level of p38 MAPK expression in these cells.
Materials and methods
Cell culture and treatment
FA-6 and T3M-4 cells were maintained in RPMI 1640 sup-
plemented with 10% FBS, 1% P/S and 1% B16 granulo-
cyte-macrophage colony stimulating factor (GM-CSF)
conditioned media, and incubated at 37°C, 5% CO2.
P38 MAPK transfection
The full length reading frame of p38 MAPK (NM_002745)
was amplified by PCR and cloned into the pCMV-script
vector (Stratagene, USA) to give pCMVp38+. As a control,
we also cloned the p38 MAPK reading frame lacking the
ATG translation start site (pCMVp38). Transfections for
both FA-6 and T3M-4 were performed in 35 mm plates
with cells at 80% confluency. 2 μg of each vector were
used per plate, together with 6 μl of GeneJammer transfec-
tion reagent (Stratagene, USA), with other conditions as
described in the manufacturer's protocol.
RNA extraction and RT-QPCR
Total RNA was extracted from FA-6 or T3M-4 cells using
an RNeasy mini kit (Qiagen). 1 μg of RNA was used in
subsequent reverse transcription reactions. This was
mixed with a poly T15 oligo to 5 μg/ml and heated to
75°C for 5 minutes. After cooling on ice, the following
additional reagents were added; dNTPs to 0.4 mM, RNase
OUT (Promega) to 1.6 u/μl, Moloney Murine Leukemia
Virus Reverse Transcriptase (M-MLRvT) RnaseH- point
mutant (Promega) to 8 u/μl and the appropriate buffer
(supplied by the manufacturer) to x1 concentration. The
mixture was incubated for one hour at 37°C, heated to
70°C for two minutes and cooled on ice.
QPCR reactions were all performed in a total volume of
50 μl. For each we used 1 μl of the M-MLRvT reaction (as
described above), 0.2 nmols of each primer and 25 μl of
pre-mixed QPCR components (Sigma). All reactions were
cycled at 94°C for 30 seconds, 55°C for 30 seconds and
72°C for 60 seconds, for 45 cycles.
QPCR was performed using the SYBR green labeling kit
from Sigma. Thermal cycling and fluorescence detection
was by a MX4000 (Stratagene Inc., USA). Semi-quantita-
tive data was obtained by using measurements three
cycles after reactions had risen above the base line, and
were clearly in exponential increase. β-actin was used as a
control for RNA recovery and cDNA synthesis, and all val-
ues are presented as a ratio of target to β-actin signal.
Detection of p38 MAPK protein by western blotting
Whole cell lystaes were prepared from FA-6 and T3M-4
cells and 15 μg was used for each detection. Blotting was
performed using the Western Breeze Chemuliminescent
kit (anti-rabbit, Invitrogen, UK), according to the manu-
factures instructions. Primary detection was by a rabbit
anti-p38 MAPK antibody (ab7952, AbCam, UK), at a final
concentration of 0.1 μg/ml. Blots were stripped and re-
probed with rabbit anti-beta actin (Abcam, UK, ab8227)
to act as a loading control.
siRNA silencing of p38 MAPK in T3M-4 cells
Cultured T3M-4 cells were plated in triplicate the day
before the transfection procedure was started. Pre-vali-
dated siRNA (Ambion, id # 1634) was transfected at a
final concentration of 100 nM. RNA was extracted from
the cells 48 hours after transfection. mRNA levels were
measured by real-time RT-PCR, as described above. As a
positive control, we also transfected with siRNA to target
GAPDH, and with a non-targeting siRNA, to act as a neg-
ative control. Both of these siRNAs are supplied in the
Ambion 'siRNA starter kit', which was used for all of the
transfections, using the manufacturer's protocol.
Results and discussion
In order to compare the expression of CaR and its down-
stream signaling components in PTHrP-expressing and
non-expressing PAC lines, we selected FA-6 [12] and T3M-
4 [15]. The former was established from a biopsied lymph
node removed from a patient with PAC associated with
humoral hypercalcaemia of malignancy, and secretes
both PTHrP together with a TNFα-type bone reabsorbing
activity. Likewise, T3M-4 was also established from a
biopsied lymph node taken from a PAC patient, but
unlike FA-6, T3M-4 is not known to secrete a bone-reab-
sorbing activity.
In order to assess the transcription of CaR and its down-
stream signaling components, we extracted RNA fromMolecular Cancer 2006, 5:51 http://www.molecular-cancer.com/content/5/1/51
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T3M-4 and FA-6 cells in culture. The relative amounts of
specific transcripts in this pathway were then determined
by quantitative PCR (QPCR). In brief, this pathway con-
sists of CaR itself linked via an adaptor protein (Grb-2) to
a guanine exchange factor (GEF), which upon Ca2+ signal-
ing catalyses the exchange of GTP for GDP by membrane
bound Ras protein. GTP-bound Ras then activates MAP3K
that in turn phosphorylates and thereby activates MAP2K,
and this then activates p38 MAPK in the same manner (Fig
1; reviewed in ref [16]). The QPCR results indicate that
whilst the majority of the CaR signaling pathway compo-
nents, including CaR itself, are expressed at essentially the
same level in the two different cell lines, p38 MAPK is spe-
cifically downregulated in FA-6 cells. The difference in
expression levels is approximately 8 fold. This difference
is also reflected at the protein level, as western blotting
whole cell protein extracts from both cell lines reveals a
significantly lower expression of p38 MAPK protein in FA-
6 cells (Fig 2).
The relatively low level of p38 MAPK expression in FA-6
cells suggests that FA-6 cells could have a different Ca2+
The relative expression of components in the CaR/p38 MAPK signaling cascade, as determined by QPCR in FA-6 (F) and T3M- 4 (T) pancreatic carcinoma cell lines Figure 1
The relative expression of components in the CaR/p38 MAPK signaling cascade, as determined by QPCR in FA-6 (F) and T3M-
4 (T) pancreatic carcinoma cell lines. The relative level of expression of each component is shown below a schematic pathway 
for this signaling cascade. Each value shown is a mean of six independent experiments; error bars represent the standard error 
of the mean.Molecular Cancer 2006, 5:51 http://www.molecular-cancer.com/content/5/1/51
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sensitivity to T3M-4 cells. In order to test this, we meas-
ured the proliferation of cells in the presence of low (0.5
mM) and high (4 mM) Ca2+ (Fig 3). Although the rate of
proliferation is similar for both cell types at the lower con-
centration, a higher concentration of Ca2+ causes a signif-
icant reduction in T3M-4 proliferation but not of FA-6
proliferation. To test whether the relatively low expression
of p38MAPK could be responsible for this difference, we
transfected FA-6 cells with a vector containing the full
length reading frame of p38MAPK (pCMVp38+), or with
one containing the same insert but without the ATG start
codon (pCMVp38-) to act as a control. FA-6 cells trans-
Forced expression of p38 MAPK sensitizes FA-6 cells to high  Ca2+ concentrations Figure 5
Forced expression of p38 MAPK sensitizes FA-6 cells to high 
Ca2+ concentrations. FA-6 cells were transfected with 
pCMVp38+ or pCMVp38- and cultured in high Ca2+. The 
percentage increase in cell number over 24 hours is shown 
for the mean of three experiments, error bars show the 
SEM.
Western blot detection of p38 MAPK protein in FA-6 and  T3M-4 cells Figure 2
Western blot detection of p38 MAPK protein in FA-6 and 
T3M-4 cells. Beta-actin is included as a loading control.
Transfection of FA-6 cells with p38 MAPK Figure 4
Transfection of FA-6 cells with p38 MAPK. FA-6 cells were 
tansfected with a full length clone of p38 MAPK 
(pCMVp38+), or with an almost identical clone lacking a 
translation start site (pCMVp38-). The levels of p38 MAPK 
protein were subsequently analyzed by western blotting 
using lysates of treated cells and an anti- p38 MAPK antibody. 
Loading control: β-actin.
FA-6 cells, but not T3M-4 cells continue to proliferate when  exposed to high concentrations (4 mM) of Ca2+ Figure 3
FA-6 cells, but not T3M-4 cells continue to proliferate when 
exposed to high concentrations (4 mM) of Ca2+. Results are 
the mean of three experiments, error bars show the SEM.Molecular Cancer 2006, 5:51 http://www.molecular-cancer.com/content/5/1/51
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fected with pCMVp38+ showed significantly raised levels
of p38MAPK protein (Fig 4), and also a considerable
decrease in proliferation when in the presence of 4 mM
Ca2+  (Fig 5), whilst cells FA-6 cells transfected with
pCMVp38- did not.
If a reduced level of p38 MAPK expression is responsible
for blocking the response to Ca2+ in FA-6 cells, then it is
possible that reducing the relatively high levels of p38
MAPK in T3M-4 cells could also reduce their sensitivity to
Ca2+. To address this, we targeted p38 MAPK in T3M-4
cells using a sequence specific short interfering RNA
(siRNA). This resulted in a substantial (72%) reduction in
p38 MAPK RNA, as measured by RT-QPCR (Fig 6), and a
corresponding reduction in p38 MAPK protein (Fig 7).
T3M-4 cells treated in this way showed a reduced sensitiv-
ity to Ca2+ mediated inhibition of proliferation, whilst
untreated cells and those treated with a non-targeting
siRNA did not (Fig 8).
The analysis of differential transcription between cells and
tissues is becoming increasingly important in diagnosis
and prognosis, and also in understanding the physiology
of different cell types. Studies using micro array based
approaches have indicated that changes in the transcrip-
tion of relatively small groups of genes may underlie the
difference between normal and malignant states [17], and
that these genes can be subdivide into functional distinct
subclasses, for example those involved in proliferation
and growth. In this study, we show that a single, stable
transcriptional change between different pancreatic carci-
noma cell lines may influence their response to distinct
environmental signals, in this case the extracellular con-
centration of Ca2+. This change is in the transcription of
p38 MAPK, a key component of the CaR-mediated prolif-
erative/anti-proliferative affect of Ca2+ [18]. It is intrigu-
ing that p38 MAPK should be so strongly downregulated
in FA-6 cells, which are derived from a tumour that both
Cells transfected with siRNA targeting p38 MAPK show sig- nificantly increased proliferation in the presence of 4 mM  Ca2+ Figure 8
Cells transfected with siRNA targeting p38 MAPK show sig-
nificantly increased proliferation in the presence of 4 mM 
Ca2+. T3M-4 cells were transfected with control or p38 
MAPK siRNA, as shown and were cultured in medium sup-
plemented with 4 mM Ca2+. The proliferation of each popu-
lation is shown relative to that of untreated cells over 48 
hours.
siRNA-mediated depletion of p38 MAPK RNA in T3M-4 cells Figure 6
siRNA-mediated depletion of p38 MAPK RNA in T3M-4 
cells. The relative expression of p38 MAPK is shown as a 
proportion of β-actin. Cells were either left untreated or 
were transfected with control siRNA or siRNA targeting p38 
MAPK. The results shown are the mean of three experi-
ments, error bars represent the SEM.
Western blot detection of p38 MAPK protein in untreated,  control siRNA and p38 MAPK siRNA transfected T3M-4  cells Figure 7
Western blot detection of p38 MAPK protein in untreated, 
control siRNA and p38 MAPK siRNA transfected T3M-4 
cells. β-actin is included as a loading control.Publish with BioMed Central    and   every 
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promotes hypercalcaemia through PTHrP secretion whilst
escaping its anti-proliferative effects seen in other PACs.
Greatly reduced p38 MAPK expression is thus an example
of a specific change in the CaR signaling pathway that can
block its activity, and of a selection for a specific transcrip-
tomic change that allows an escape from anti-proliferative
signals.
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